[1] PHUA L C, GOH S, TAI D W M, et al. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine[J]. Cancer Chemother Pharmacol, 2018, 81(2): 277-289.
[2] YUAN Y, LI D, LI H, et al. YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells[J]. Mol Med Rep, 2016, 13(1): 237-242.
[3] ZHANG H, VON GISE A, LIU Q, et al. Yap1 is required for endothelial to mesenchymal transition of the atrioventricular cushion[J]. J Biol Chem, 2014, 289(27): 18681-18692.
[4] ZHANG Q, ZHANG Y, PARSELS J D, et al. Fbxw7 deletion accelerates kras(G12D)-driven pancreatic tumorigenesis via yap accumulation[J]. Neoplasia, 2016, 18(11): 666-673.
[5] 史梦婕, 邵松军, 李洁媚, 等. Hippo通路与肿瘤相关性研究进展[J]. 中国细胞生物学学报, 2014, 36(3): 361-365.
[6] DIEPENBRUCK M, WALDMEIER L, IVANEK R, et al. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition[J]. J Cell Sci, 2014, 127(Pt 7): 1523-1536.
[7] PEI T, LI Y, WANG J, et al. YAP is a critical oncogene in human cholangiocarcinoma[J]. Oncotarget, 2015, 6(19): 17206-17220.
[8] VLUG E J, VAN DE VEN R A, VERMEULEN J F, et al. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer[J]. Cell Oncol (Dordr), 2013, 36(5): 375-384.
[9] SHEN S, GUO X, YAN H, et al. A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis[J]. Cell Res, 2015, 25(9): 997-1012.
[10] WEI H, WANG F, WANG Y, et al. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex[J]. Cancer Sci, 2017, 108(3): 478-487.
[11] ZHANG Y, ZHOU M, WEI H, et al. Furin promotes epithelial-mesenchymal transition in pancreatic cancer cells via Hippo-YAP pathway[J]. Int J Oncol, 2017, 50(4): 1352-1362.
[12] ZHU Z M, XU Y F, SU Q J, et al. Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma[J]. Mol Cell Biochem, 2014, 388(1-2): 39-49.
[13] HAN D, BYUN S H, PARK S, et al. YAP/TAZ enhance mammalian embryonic neural stem cell characteristics in a Tead-dependent manner[J]. Biochem Biophys Res Commun, 2015, 458(1): 110-116.
[14] HIRATE YSASAKI H. The role of angiomotin phosphorylation in the Hippo pathway during preimplantation mouse de-velopment[J]. Tissue Barriers, 2014, 2(1): e28127.
[15] GRETEN F R. YAP1 takes over when oncogenic K-Ras slumbers[J]. Cell, 2014, 158(1): 11-12.
[16] KAPOOR A, YAO W, YING H, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic can-cer[J]. Cell, 2014, 158(1): 185-197.
[17] 宋娟,叶小群. Hippo-YAP信号通路为靶点的肿瘤治疗研究进展[J]. 中国肿瘤临床, 2015(17): 876-880.
[18] HSU P D, SCOTT D A, WEINSTEIN J A, et al. DNA targeting specificity of RNA-guided Cas9 nucleases[J]. Nat Biotechnol, 2013, 31(9): 827-832.
[19] RAN F A, HSU P D, LIN C Y, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity[J]. Cell, 2013, 154(6): 1380-1389.
[20] 周文媛, 任军, 纪元, 等. N-乙酰氨基半乳糖转移酶6对乳腺癌细胞MCF-7增殖和迁移的影响[J]. 温州医科大学学报, 2017, 47(12): 864-868, 874.
[21] 郑斌, 吴齐全, 周克文, 等. 转录因子SOX7对前列腺癌PC-3细胞生物学活性的影响及其机制[J]. 温州医科大学学报, 2017, 47(9): 678-682.
[22] ZHANG Q, CHEN X, ZHANG X, et al. Knockdown of TMEM14A expression by RNAi inhibits the proliferation and invasion of human ovarian cancer cells[J]. Biosci Rep, 2016, 36(1): e00298.
[23] CHIU K Y, WU C C, CHIA C H, et al. Inhibition of growth, migration and invasion of human bladder cancer cells by antrocin, a sesquiterpene lactone isolated from Antrodia cinnamomea, and its molecular mechanisms[J]. Cancer Lett, 2016, 373(2): 174-184. |